Mitoxantrone and Hepatic Toxicity
Authors: PAOLO ALBERTO PACIUCCI
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 November 1986Mitoxantrone and Hepatic ToxicityPAOLO ALBERTO PACIUCCI, M.D., NANCY T. SKLARIN, M.D.PAOLO ALBERTO PACIUCCI, M.D.Search for more papers by this author, NANCY T. SKLARIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-5-805_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The use of mitoxantrone as an antineoplastic drug was reviewed recently by Shenkenberg and Von Hoff (1), who described its biochemistry, pharmacology, activity, and associated toxicities. Since 1979 we have investigated mitoxantrone extensively in the treatment of acute leukemias, lymphomas, and breast carcinomas. We have noted a toxicity that the reviewers failed to mention, hepatotoxicity.In our study (2) of 26 patients with primarily refractory or relapsed acute lymphocytic leukemia, acute myelocytic leukemia, and blastic phase chronic myelocytic leukemia, mitoxantrone was given alone at a dosage of 8 to 20 mg/m2 body surface area intravenously daily for...References1. SHENKENBERGVON HOFF TD. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med. 1986;105:67-81. LinkGoogle Scholar2. PACIUCCIOHNUMACUTTNERSILVERHOLLAND PTJRJ. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res. 1983;43:3919-22. MedlineGoogle Scholar3. ROBOZPACIUCCISILIDESGREAVESHOLLAND JPDJJ. Detection and quantification of mitoxantrone in human organs. Cancer Chemother Pharm. 1984;13:67-8. CrossrefMedlineGoogle Scholar4. GOLDSMITHOHNUMAROBOZJAFFREYGREENSPANHOLLAND MTJIEJ. Phase I clinical and pharmacological evaluation of mitoxantrone. Proc Am Assoc Cancer Res. 1981;17:C-224. Google Scholar1. VON HOFFPOLLARDKUHNMURRAYCOLTMAN DEJEC. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis ((2-[(2-hydroxy-ethyl) amino] ethyl)amino)-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res. 1980;40:1516-8. MedlineGoogle Scholar2. PACIUCCIOHNUMACUTTNERSILVERHOLLAND PTJRJ. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res. 1983;43:3919-22. MedlineGoogle Scholar3. VON HOFFTURNERMCCONNELLCOLTMAN DJKC. The acute toxicities of Novantrone. In: COLTMAN CA JR, ed. The Current Status of Novantrone: Proceedings of a Symposium. New York: Park Row Publishers, Inc. ; 1985:29-34. Google Scholar4. WILKINSONBEVANEDMUNDSONLUCAS PKJS. Pharmacokinetics of mitoxantrone in patients with metastatic breast cancer (MBC) with liver metastases [Abstract]. Proc Am Soc Clin Oncol. 1986;5:30. Google Scholar5. CHLEBOWSKITONGWOODWARD RMD. Mitoxantrone administration in patients with hepatic dysfunction. In: COLTMAN CA JR, ed. The Current Status of Novantrone: Proceedings of a Symposium. New York: Park Row Publishers, Inc. ; 1985:23-8. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Mount Sinai Hospital New York, NY 10029 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAcute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapyHepatotoxicity of ChemotherapyHepatotoxicity of chemotherapyHepatotoxicity of ChemotherapyHEPATOTOXICITY OF CHEMOTHERAPEUTIC AND ONCOLOGIC AGENTSFulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemiaPhase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancerAccidental overdose of mitoxantrone in three patients 1 November 1986Volume 105, Issue 5Page: 805-806KeywordsAdverse reactionsBiochemistryBody surface areaBreast cancerChronic myelocytic leukemiaLeukemiaLymphomaPharmacologyPrecursor cellsToxicity Issue Published: 1 November 1986 PDF downloadLoading ...